Disruption of IGF signaling in early hepatocellular carcinoma and pre-clinical efficacy of anti-IGF1R blocking therapies

被引：1
|
作者：
Tovar, V. [1 ,2 ]
Alsinet, C. [1 ,2 ]
Cabellos, L. [1 ,2 ]
Sole, M. [1 ,2 ]
Villanueva, A. [3 ]
Chiang, D. [5 ]
Moyano, S. [1 ,2 ]
Schwartz, M. [3 ]
Mazzaferro, V. [4 ]
Bruix, J. [1 ,2 ]
Llovet, J. M. [1 ,2 ,3 ]
机构：
[1] IDIBAPS, Hosp Clin, Liver Unit, HCC Translat Lab,BCLC Grp, Barcelona, Spain
[2] IDIBAPS, Hosp Clin, Dept Pathol, Barcelona, Spain
[3] Mt Sinai Sch Med, Div Liver Dis, Mt Sinai Liver Canc Program, New York, NY USA
[4] Ist Nazl Tumori, I-20133 Milan, Italy
[5] Broad Inst, Canc Program, Boston, MA USA
来源：
JOURNAL OF HEPATOLOGY | 2008年 / 48卷
关键词：
D O I：
10.1016/S0168-8278(08)60004-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2
引用
收藏
页码：S3 / S3
页数：1
相关论文
共 50 条
  • [21] Anti-IGF1R therapy with dalotuzumab is efficacious in a sub-set of KRAS mutant cetuximab refractory CRC models
    Sathyanarayanan, S.
    Watkins, D. J.
    Sykes, K.
    Howard, S.
    Valentine, E.
    Bloecher, A.
    Clark, E. A.
    Hsu, K.
    Cunningham, D.
    Winter, C.
    EJC SUPPLEMENTS, 2010, 8 (07): : 75 - 75
  • [22] Bioinformatic identification of IGF1 as a hub gene in hepatocellular carcinoma (HCC) and in-vitro analysis of the chemosensitizing effect of miR-379 via suppressing the IGF1/IGF1R signaling pathway
    Huang, D. -J.
    Huang, J. -Z.
    Yang, J.
    Li, Y. -H.
    Luo, Y. -C.
    He, H. -Y.
    Huang, H. -J.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (24) : 5098 - 5106
  • [23] Molecular mechanisms of resistance to anti-IGF-1R therapies in Ewing's sarcoma
    Garofalo, Cecilia
    Manara, Maria Cristina
    Marino, Maria Teresa
    Lollini, Pier Luigi
    Picci, Piero
    Scotlandi, Katia
    CANCER RESEARCH, 2011, 71
  • [24] Activity of the IGF1-R/IR Inhibitor OSI-906 in Non-small Cell Lung Cancer (NSCLC): Pre-Clinical and Early Clinical Experience
    Kim, E. S.
    Puzanov, I.
    Buck, E.
    Gedrich, R.
    Poondru, S.
    Carden, C.
    Kaye, S. B.
    Davies, A.
    Nava-Parada, P.
    Miglarese, M. R.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S543 - S543
  • [25] Association of IGF1R polymorphisms with the development of HBV-related hepatocellular carcinoma
    Xie, H. -Y.
    Xing, C. -Y.
    Wei, B. -J.
    Xu, X.
    Wu, J.
    Chen, L. -M.
    Cao, G. -Q.
    Chen, H.
    Chen, K. -J.
    Yin, S. -Y.
    Wu, L. -M.
    Zhou, L.
    Zheng, S. -S.
    TISSUE ANTIGENS, 2014, 84 (03): : 264 - 270
  • [26] Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well- differentiated neuroendocrine tumors
    Dasari, Arvind
    Phan, Alexandria
    Gupta, Sanjay
    Rashid, Asif
    Yeung, Sai-Ching Jim
    Hess, Kenneth
    Chen, Helen
    Tarco, Emily
    Chen, Huiqin
    Wei, Caimiao
    Anh-Do, Kim
    Halperin, Daniel
    Meric-Bernstam, Funda
    Yao, James
    ENDOCRINE-RELATED CANCER, 2015, 22 (03) : 431 - 441
  • [27] In vivo pharmacology of MEDI-573, an anti-IGF-I and IGF-II antibody that targets the IGF-1R and IR-A signaling pathways
    Gao, Jin
    Chesebrough, Jon
    Lam, Brandon
    Funelas, Cherryle
    Jallal, Bahija
    Coats, Steven
    Tabrizi, Mohammad
    Chang, Yong
    CANCER RESEARCH, 2009, 69
  • [28] Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling
    Maruwge, Wessen
    D'Arcy, Padraig
    Folin, Annika
    Brnjic, Slavica
    Wejde, Johan
    Davis, Anthony
    Erlandsson, Fredrik
    Bergh, Jonas
    Brodin, Bertha
    ONCOTARGETS AND THERAPY, 2008, 1 : 67 - 78
  • [29] Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling
    E Flashner-Abramson
    S Klein
    G Mullin
    E Shoshan
    R Song
    A Shir
    Y Langut
    M Bar-Eli
    H Reuveni
    A Levitzki
    Oncogene, 2016, 35 : 2675 - 2680
  • [30] Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling
    Flashner-Abramson, E.
    Klein, S.
    Mullin, G.
    Shoshan, E.
    Song, R.
    Shir, A.
    Langut, Y.
    Bar-Eli, M.
    Reuveni, H.
    Levitzki, A.
    ONCOGENE, 2016, 35 (20) : 2675 - 2680
12345